Evidence map›Paper›PMID 25578798›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015

Quantification of the Serotonin 1A Receptor Using PET: Identification of a Potential Biomarker of Major Depression in Males.

Joshua Kaufman, Gregory M Sullivan, Jie Yang, R Todd Ogden, Jeffrey M Miller, Maria A Oquendo, J John Mann, Ramin V Parsey, Christine DeLorenzo

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Review
  3. 5-HTScientific reports · 2025
    Article
  4. Article
  5. Sex-specific and developmental effects of early life adversity on stress reactivity are rescued by postnatal knockdown of 5-HTNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. European psychiatry : the journal of the Association of European Psychiatrists · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. NRM 2021 Abstract Booklet.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Joshua KaufmanStony Brook University, Stony Brook, NY, USA.
Gregory M SullivanColumbia University College of Physicians and Surgeons, New York City, NY, USA.
Jie YangStony Brook University, Stony Brook, NY, USA.
R Todd OgdenColumbia University School of Public Health, New York City, NY, USA.
Jeffrey M MillerColumbia University College of Physicians and Surgeons, New York City, NY, USA.
Maria A OquendoColumbia University College of Physicians and Surgeons, New York City, NY, USA.
J John MannColumbia University College of Physicians and Surgeons, New York City, NY, USA.
Ramin V ParseyStony Brook University, Stony Brook, NY, USA.
Christine DeLorenzoStony Brook University, Stony Brook, NY, USA.
Columbia University · USStony Brook University · US

Funding

THE NEUROBIOLOGY OF SUICIDAL BEHAVIORP50MH062185 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MANN, JOSEPH JOHN · 2000 to 2009
$21.7M
Neurobiology of Depression and AntidepressantsR01MH040695 · NIMH · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI MANN, JOSEPH JOHN · 1986 to 2014
$7.1M
Supplement to Lithium's Molecular Mechanism of Action and the Pathology of Bipolar DisordersR01MH090276 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI PARSEY, RAMIN V. · 2011 to 2015
$4.2M
Biological Predictors of Response to AntidepressantsR01MH074813 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PARSEY, RAMIN V. · 2006 to 2010
$2.3M
Characterization of a New Metabotropic Glutamate Receptor Subtype 5 PET LigandK01MH091354 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI DELORENZO, CHRISTINE · 2011 to 2014
$691k
NIMH NIH HHS K01 MH091354NIMH NIH HHS K01MH091354NIMH NIH HHS P50 MH062185NIMH NIH HHS P50MH062185NIMH NIH HHS R01 MH040695NIMH NIH HHS R01 MH074813NIMH NIH HHS R01MH074813NIMH NIH HHS R01 MH090276NIMH NIH HHS R01MH090276NIMH NIH HHS R01MH40695
6 · The paper itself

Abstract

Multiple lines of research have implicated the serotonin 1A (5-HT1A) receptor in major depressive disorder (MDD). Despite this, quantification of 5-HT1A is yet to yield a clinically relevant MDD biomarker. One reason may be that reported sex differences in the serotonergic system confound the comparison between diagnostic groups. Therefore, this study sought to determine whether differences in 5-HT1A binding between depressed and control subjects are affected by sex. Using positron emission tomography (PET), serotonin 1A binding was quantified in 50 patients with MDD (34 female, 16 male) and 57 healthy controls (32 female, 25 male). The subjects' 5-HT1A density (BPF, equal to the product of the density of available receptors and tracer affinity), was determined by using the PET tracer [carbonyl-C-11]-WAY-100635, a selective 5-HT1A antagonist. Results indicated that male MDD subjects had a 67.0% higher BPF across 13 brain regions compared with male controls (df=103, p<0.0001). The greatest difference between MDD subjects and controls was in the raphe (132%, p=0.000). Furthermore, by using a threshold, male controls can be distinguished from depressed males with high sensitivity and specificity (both >80%). In females, the separation between diagnostic groups yields much lower sensitivity and specificity. This data therefore suggests a specific biosignature for MDD in males. Identification of such a biosignature could provide a deeper understanding of depression pathology, help identify those at highest risk, and aid in the development of new therapies. Further, these findings suggest that combining male and female cohorts may not be optimal for some MDD studies.

Indexed as

Positron-Emission TomographyAdolescentAdultAgedCarbon IsotopesGenotypeHumansMagnetic Resonance ImagingMajor Depressive DisorderMaleMiddle AgedPiperazinesPyridinesRaphe NucleiReceptor, Serotonin, 5-HT1ASerotonin AntagonistsCarbon IsotopesN-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamidePiperazinesPyridinesReceptor, Serotonin, 5-HT1ASerotonin Antagonists

Identifiers

PMID25578798
PMCPMC4915251
OpenAlexW2015076008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.